Fragment-based hit identification: thinking in 3D

Andrew D. Morley (Lead / Corresponding author), Angelo Pugliese, Kristian Birchall, Justin Bower, Paul Brennan, Nathan Brown, Tim Chapman, Martin Drysdale, Ian H. Gilbert, Swen Hoelder, Allan Jordan, Steven V. Ley, Andy Merritt, David Miller, Martin E. Swarbrick, Paul G. Wyatt (Lead / Corresponding author)

    Research output: Contribution to journalArticlepeer-review

    127 Citations (Scopus)


    The identification of high-quality hits during the early phases of drug discovery is essential if projects are to have a realistic chance of progressing into clinical development and delivering marketed drugs. As the pharmaceutical industry goes through unprecedented change, there are increasing opportunities to collaborate via pre-competitive networks to marshal multifunctional resources and knowledge to drive impactful, innovative science. The 3D Fragment Consortium is developing fragment-screening libraries with enhanced 3D characteristics and evaluating their effect on the quality of fragment-based hit identification (FBHI) projects.
    Original languageEnglish
    Pages (from-to)1221-1227
    Number of pages7
    JournalDrug Discovery Today
    Issue number23-24
    Publication statusPublished - Dec 2013


    Dive into the research topics of 'Fragment-based hit identification: thinking in 3D'. Together they form a unique fingerprint.

    Cite this